Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:02:30.600Z.
Calculation as of: 2026-10-06T17:02:30.600Z.
Quote observation: 2026-10-06T17:00:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 451a64ce4da380df6ab4c5027584c6fd3c25ecc0cb3c19eab7daced69cd0f5b9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$34.11M
EV/EBIT Ratio
N/A
TTM Avg
50.30x
3Y Avg
467.13x
5Y Avg
265.91x
Market Cap
$33.15M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $34.66M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.92M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $34.11M | N/A | 50.30x | 467.13x | 265.91x |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.92M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.31M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.66M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.80M | N/A | 8.66x | 44.05x | 43.98x |
| EUDA Health Holdings Limited (EUDA)vs › | $33.15M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | N/A | N/A | N/A | N/A |
| Scilex Holding Company (SCLX)vs › | $33.03M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
